Firefly Neuroscience (AIFF) said Wednesday it is collaborating with Bright Minds Biosciences (DRUG) to use Firefly's AI-driven Brain Network Analytics technology to analyze data from Bright Minds' phase 1 study of its lead compound, BMB-101.
Financial details weren't disclosed.
The study on Bright Minds' lead compound, BMB-101, utilized electroencephalogram, or EEG headsets from Firefly's partner, Zeto, and showed positive results through qEEG data analysis with recordings taken at multiple time points.
Firefly Neuroscience said that the phase 1 trial is complete, and BMB-101 is now ready for phase 2.
Shares of Firefly were up more than 22%, while Bright Minds retreated over 35% in recent Wednesday trading.
Price: 3.84, Change: +0.71, Percent Change: +22.52
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.